Disease · MONDO_0005129

cataract

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cataract. Diseases, record MONDO_0005129. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005129

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cataract; Open Targets
Open Targets ID: MONDO_0005129; Open Targets
Other names: CATARACT NEC, CATARACT W RADIATION, CATARACT W SYNDROME NEC, Cat. - Cataract, Cataract (M-54510), Cataract (disorder), Cataract (morphologic abnormality), Cataract NOS, Cataract NOS (disorder), Cataract associated with other disorders, Cataract associated with other syndromes, Cataract associated with other syndromes (disorder), Cataract associated with radiation and other physical influences, Cataract form, Cataract form (observable entity), Cataract, Membranous, Cataracts, Cataracts, Membranous, Clouding of the lens of the eye, Cloudy lens, Lens opacities, Lens opacity, Lenticular opacity, Membranous Cataract, Membranous Cataracts, Opacities, Lens, Opacity, Lens, Other cataract, Other cataract (disorder), Other cataract NOS, Other cataract NOS (disorder), Pseudoaphakia, Pseudoaphakias, Unspecified cataract, cataract (disease), opacity of the lens; Open Targets
Disease Ontology: DOID:83; Disease Ontology
MeSH: D002386; MeSH
NCI Thesaurus: C26713; NCI Thesaurus
Highest stage of its drugs: Approval, for 8 of its 50 drugs, from DailyMed and TTD; Open Targets

Drugs50

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DICLOFENAC	CHEMBL139	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
BROMFENAC SODIUM	CHEMBL3181947	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
KETOROLAC TROMETHAMINE	CHEMBL1201124	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
ACETYLCHOLINE	CHEMBL667	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ACETYLCHOLINE CHLORIDE	CHEMBL1184	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CARBACHOL	CHEMBL14	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
NEPAFENAC	CHEMBL1021	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TIRILAZAD MESYLATE	CHEMBL3989513	Small molecule	Approval	TTD	1	0	0	Drugs and targets
LIDOCAINE	CHEMBL79	Small molecule	Phase 3	ClinicalTrials.gov	7	7	6	Drugs and targets
PHENYLEPHRINE	CHEMBL1215	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 50

See all 50 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PTGS1	Cyclooxygenase	6	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	6	Cyclooxygenase inhibitor	Approval	https://conductscience.org/library/genes/5743	Drugs and targets
SCN4A	Sodium channel alpha subunit	6	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6329	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	5	Muscarinic acetylcholine receptor M3 agonist; Muscarinic acetylcholine receptor M3 antagonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
SCN10A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	5	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets

1 to 10 of 53

See all 53 targets

Trials38

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02101359	Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery	Phase 3	609	2014-09-25	Cataract	LIDOCAINE, PHENYLEPHRINE, TROPICAMIDE	Its record names the disease	ClinicalTrials.gov
NCT04685538	Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.	Phase 3	338	2022-10-27	Cataract	CHLOROPROCAINE, TETRACAINE	Its record names the disease	ClinicalTrials.gov
NCT01576952	Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery Subjects	Phase 3	268	2016-07-13	Ocular Inflammation	BROMFENAC	Its record names the disease	ClinicalTrials.gov
NCT01808547	Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects	Phase 3	268	2016-07-13	Ocular Inflammation	BROMFENAC	Its record names the disease	ClinicalTrials.gov
NCT00854061	Study of T-PRED(TM) Compared to Pred Forte(R) II	Phase 3	172	2020-10-20	Cataract	PREDNISOLONE, PREDNISOLONE ACETATE, TOBRAMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00703781	Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery	Phase 3	126	2011-12-09	Cataract	BROMFENAC	Its record names the disease	ClinicalTrials.gov
NCT02132312	A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement	Phase 3	78	2021-07-22	Unilateral Cataract Extraction, Congenital Cataract	PHENYLEPHRINE	Its record names the disease	ClinicalTrials.gov
NCT01602068	Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Delivery Prior to Implantation of a Posterior Chamber IOL	Phase 2	45	2018-05-21	Cataract	DEXAMETHASONE PHOSPHORIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02909140	Optimal Method for Mydriasis in Cataract Surgery	Not applicable	3	2019-09-10	Cataract	CYCLOPENTOLATE, EPINEPHRINE, LIDOCAINE, PHENYLEPHRINE	Its record names the disease	ClinicalTrials.gov
NCT03653520	Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)	Not applicable	651		Cataract	DIAZEPAM, MIDAZOLAM, ONDANSETRON, TRAMADOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 38

See all 38 trials

Comparisons in its trials16

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
T2380 vs Reference Group: serious adverse events	4 of 295	6 of 296	591	NCT02101359	Trial comparisons
Chloroprocaine 3% vs Tetracaine 0.5%: deaths from any cause	0 of 167	0 of 171	338	NCT04685538	Trial comparisons
Chloroprocaine 3% vs Tetracaine 0.5%: serious adverse events	0 of 167	0 of 171	338	NCT04685538	Trial comparisons
T-Pred vs Pred-Forte: serious adverse events	1 of 162	1 of 162	324	NCT00854061	Trial comparisons
ISV-303 vs Vehicle: serious adverse events	1 of 170	1 of 85	255	NCT01808547	Trial comparisons
ISV-303 vs Vehicle: serious adverse events	0 of 169	1 of 85	254	NCT01576952	Trial comparisons
ISV-303 vs Vehicle: Ocular Inflammation	96 of 168	16 of 85	253	NCT01576952	Trial comparisons
ISV-303 vs Vehicle: Ocular Inflammation	64 of 168	19 of 85	253	NCT01808547	Trial comparisons
Bromfenac vs Placebo: Number of Participants That Are Pain Free	51 of 63	46 of 63	126	NCT00703781	Trial comparisons
Bromfenac vs Placebo: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero	28 of 63	20 of 63	126	NCT00703781	Trial comparisons

1 to 10 of 16

See all 16 comparisons in its trials

Papers from its trials11

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36369026	RESULT	1	PubMed
34838503	RESULT	1	PubMed
31668347	RESULT	1	PubMed
31114165	RESULT	1	PubMed
29661413	RESULT	1	PubMed
25085962	RESULT	1	PubMed
38489057	DERIVED	1	PubMed
34562489	DERIVED	1	PubMed
32126990	DERIVED	1	PubMed
26531052	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005129

GET https://conductscience.org/api/diseases/v1/MONDO_0005129/drugs?page=2

API reference For AI assistants